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The 10-valent pneumococcal conjugate vaccine 
(PCV10) became available in Portugal in mid-2009 
and the 13-valent vaccine (PCV13) in early 2010. The 
incidence of invasive pneumococcal disease (IPD) in 
patients aged under 18 years decreased from 8.19 
cases per 100,000 in 2008–09 to 4.52/100,000 in 
2011–12. However, IPD incidence due to the serotypes 
included in the 7-valent conjugate vaccine (PCV7) in 
children aged under two years remained constant. 
This fall resulted from significant decreases in the 
number of cases due to: (i) the additional serotypes 
included in PCV10 and PCV13 (1, 5, 7F; from 37.6% to 
20.6%), particularly serotype 1 in older children; and 
(ii) the additional serotypes included in PCV13 (3, 6A, 
19A; from 31.6% to 16.2%), particularly serotype 19A 
in younger children. The decrease in serotype 19A 
before vaccination indicates that it was not triggered 
by PCV13 administration. The decrease of serotype 
1 in all groups, concomitant with the introduction of 
PCV10, is also unlikely to have been triggered by vac-
cination, although PCVs may have intensified and sup-
ported these trends. PCV13 serotypes remain major 
causes of IPD, accounting for 63.2% of isolates recov-
ered in Portugal in 2011–12, highlighting the potential 
role of enhanced vaccination in reducing paediatric 
IPD in Portugal.
Introduction 
Introduction of the 7-valent pneumococcal conjugate 
vaccine (PCV7) led to changes in the circulating sero-
types of Streptococcus pneumoniae and also often to 
decreases in the incidence of invasive pneumococ-
cal disease (IPD) worldwide [1-3]. Two new pneumo-
coccal conjugate vaccine (PCV) formulations are now 
commercially available and are used for children [4]. 
A 10-valent formulation (PCV10) including, in addi-
tion to the PCV7 serotypes, serotypes 1, 5 and 7F and 
a 13-valent conjugate vaccine (PCV13), including all 
PCV10 serotypes plus serotypes 3, 6A and 19A. The 
few available early reports point to the effectiveness 
of these expanded valency vaccines against the sero-
types included in their formulations [4-8].
In Portugal, PCVs are not included in the national immu-
nisation plan. Had they been, they would have been 
offered free of charge. Nevertheless, since 2001, when 
the vaccine became available, there has been a steady 
increase in PCV7 uptake bought privately, without any 
reimbursement, reaching 75% of children aged 2 years 
or under in 2008 [9]. PCV10 became available for child-
hood vaccination in mid-2009 and PCV13 in early 2010. 
Soon after PCV13 became available, according to sales 
data, this vaccine was mostly used (data not shown). 
In previous studies, we showed that significant changes 
in the serotypes causing IPD in children followed PCV7 
availability in Portugal [9,10] and that there was evi-
dence for a herd effect in the adult population [9,11,12]. 
Serotypes 1 and 7F, both included in PCV10 and PCV13, 
and serotype 19A, included in PCV13, emerged as major 
causes of paediatric (persons aged under 18 years) IPD 
in the post-PCV7 period in Portugal [10]. Given the lim-
ited information on the efficacy of PCV10 and PCV13, 
this study aimed at documenting the potential effects 
of vaccination on serotype distribution, antimicrobial 
resistance and incidence of paediatric IPD in Portugal 
from July (week 26) 2008 and June (week 25) 2012.
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Methods
Bacterial isolates
Since 2007, the Portuguese Group for the Study of 
Streptococcal Infections and the Portuguese Study 
Group of Invasive Pneumococcal Disease of the 
Paediatric Infectious Disease Society have monitored 
pneumococcal invasive infections in Portugal. During 
the study period, this involved the microbiology labo-
ratories and paediatric departments of 61 hospitals 
throughout Portugal.  The network includes centres 
covering the entire country, including all referral hospi-
tals and most centres where microbiological diagnostic 
services are available. All centres included in the study 
reported during the entire period. 
A case of IPD was defined as a person from whom an 
isolate of S. pneumoniae was recovered from a nor-
mally sterile body site (not including middle ear fluid) 
or from whom pneumococcal DNA was detected in cere-
brospinal fluid (CSF) or pleural fluid. Isolates recovered 
up to 2008 were previously characterised [9,10,13]. 
Isolates recovered from patients aged under 18 years 
between July 2008 and June 2012 were included in the 
present study. Epidemiological years were defined as 
spanning from week 26 of one year to week 25 of the 
following year. 
Only one isolate from each patient was considered. 
All strains were identified as S. pneumoniae by colony 
morphology and haemolysis on blood agar plates, 
optochin susceptibility and bile solubility. The lytA 
gene was used to identify pneumococci in CSF or pleu-
ral fluid. 
Incidences were calculated based on the entire 
Portuguese population of the relevant age groups using 
data available from the Instituto Nacional de Estatística 
[14] (Table 1), using the population data of the first cal-
endar year of each epidemiological year. The calcula-
tion assumes that all IPD cases were treated at the 61 
hospitals in our network. Four age groups were consid-
ered: infants aged less than 12 months, children aged 
12–23 months, children aged from two to four years 
and children and adolescents aged from five years to 
less than 18 years.
Serotyping and antimicrobial susceptibility 
testing
Serotyping was performed by the standard capsular 
reaction test using the chessboard system [15] and 
specific sera (Statens Serum Institut, Copenhagen, 
Denmark). Serotypes were classified into vaccine sero-
types, i.e. those included in PCV7 (serotypes 4, 6B, 
9V, 14, 18C, 19F, 23F), the additional three found in 
PCV10 (addPCV10: 1, 5, 7F), the additional three found 
Table 1
Population under 18 years during the study period, Portugal, 2008–12
Calendar year
Number of persons per age group
Total
0–11 months 12–23 months 2–4 years 5–17 years
2008 103,746 101,339 318,186 1,454,385 1,977,656
2009 98,759 103,011 311,641 1,444,426 1,957,837
2010 100,492 96,995 302,067 1,429,777 1,929,331
2011 95,703 99,519 294,727 1,412,241 1,902,190
2012 92,651 97,591 295,215 1,405,356 1,890,813
Table 2
Cases of invasive pneumococcal disease and available Streptococcus pneumoniae isolates from patients aged under 18 years, 
Portugal, July 2008–June 2012a
Epidemiological 
yearsa
Number of casesb/available isolates, by age group
Total
0–11 months 12–23 months 2–4 years 5–17 years
2008–09 54/49 32/26 36/25 40/33 162/133
2009–10 38/35 27/23 33/21 38/35 136/114
2010–11 23/20 21/19 16/13 27/25 87/77
2011–12 24/17 16/16 22/19 24/16 86/68
Total 139/121 96/84 107/78 129/109 471/392
a  From week 26 of one year to week 25 of the following year.
b  Case numbers comprise patients from whom pneumococci were isolated from a normally sterile site or pneumococcal DNA was detected in 
cerebrospinal fluid or pleural fluid.
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in PCV13 (addPCV13: 3, 6A, 19A) and non-vaccine sero-
types (NVT). 
Etest strips (AB Biodisk, Solna, Sweden) were used to 
determine the minimal inhibitory concentrations (MICs) 
for penicillin, cefotaxime, ceftriaxone and levofloxacin. 
We opted to use the Clinical and Laboratory Standards 
Institute (CLSI) guidelines because these were the 
standards in use in Portugal during the study period. 
In 2008, the CLSI changed the recommended break-
points to those currently used to interpret MIC values 
[16]. Unless otherwise stated, we have used the CLSI-
recommended breakpoints before 2008 [17] as epide-
miological breakpoints that allow comparison with 
previous studies.
Isolates were further characterised by determining their 
susceptibility to erythromycin, clindamycin, vancomy-
cin, linezolid, tetracycline, trimethoprim-sulfameth-
oxazole and chloramphenicol by the Kirby-Bauer disk 
diffusion technique, according to the CLSI recommen-
dations and interpretative criteria [16]. Macrolide resist-
ance phenotypes were identified using a double disc 
test with erythromycin and clindamycin. Simultaneous 
resistance to erythromycin and clindamycin defines 
de MLSB phenotype (resistance to macrolides, lincosa-
mides and streptogramin B) while non-susceptibility 
only to erythromycin defines the M phenotype.
Statistical analysis
Simpson’s index of diversity (SID) and respective 95% 
confidence intervals (CIs) was used to measure the 
serotype diversity [18]. The SID measures the probabil-
ity that two isolates sampled at random will not share 
the same serotype. The Cochran–Armitage test (a mod-
ification of the Pearson chi-squared test to incorporate 
a suspected ordering in the effects of the categories of 
the second variable) was used for trends with the false 
discovery rate (FDR) correction for multiple testing [19]. 
A p value of less than 0.05 was considered significant 
for all tests.
Results
Isolate collection 
Between July 2008 and June 2012, a total of 471 cases 
of IPD were reported in Portugal. Their distribution by 
age and epidemiological year is shown (Table 2) and 
the annual incidence of IPD by age group is presented 
(Figure 1). Although starting from very disparate values, 
IPD incidence decreased significantly in all age groups 
when comparing 2008–09 with 2011–12 (0–11 months, 
p<0.001; 12–23 months and 2–4 years, p=0.002; and 
5–17 years, p=0.003; all robust after FDR) (Table 3). 
For the majority of IPD cases (n=430), pneumococci 
were isolated from a normally sterile site. Only 41 
cases involved solely the identification of pneumococ-
cal DNA in CSF or pleural fluid: for these cases, no cap-
sular serotype information is available. Of the 430 IPD 
cases from whom S. pneumoniae bacteria were recov-
ered, 392 isolates were available for further charac-
terisation. The remaining 38 isolates were lost before 
reaching the central laboratory for characterisation. 
Available isolates were recovered from blood (n=335, 
85.5%), CSF (n=39, 9.9%), pleural fluid (n=15, 3.8%) 
and peritoneal fluid (n=3, 0.8%). 
Serotype distribution
We detected 39 different capsular types as well as 
non-typable isolates among the 392 available isolates 
(Figure 2). The most frequent, which accounted for 
57% (n=225) of isolates from all analysed IPD cases in 
the study period, were serotypes 1 (n=74, 18.9%), 19A 
(n=72, 18.4%), 7F (n=43, 11.0%), and 14 (n=36, 9.2%). 
The proportion of IPD cases caused by PCV7 serotypes 
remained relatively constant, at around 21%. However, 
the fraction of IPD cases that could have been poten-
tially prevented by PCV10 and PCV13 decreased signifi-
cantly during the study period, from 59.4% to 47.1% 
(p=0.008) and from 91.0% to 63.0% (p=0.024), respec-
tively. This was accompanied by an increase in sero-
type diversity when comparing 2008–09 (SID=0.846, 
CI95%: 0.810 to 0.882) with 2011–12 (SID=0.957, 95% 
CI: 0.939–0.975). 
In order to estimate the incidence of IPD due to indi-
vidual serotypes, the cases for which no isolate was 
available (n=79) were assumed to have the same sero-
type distribution as that found among isolates from 
Figure 1
Incidence of invasive pneumococcal disease in persons 
aged under 18 years, Portugal, July 2008–June 2012a
The bars represent 95% confidence intervals for the incidence 
estimates.
a  Epidemiological years: from week 26 of one year to week 25 of 
the following year.
b  Number of cases per 100,000 in specified age group.
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the same epidemiological year and age group. The 
overall incidence of IPD in all age groups due to PCV7, 
addPCV10 and addPCV13 serotypes decreased dur-
ing the study period (p=0.026, p<0.001 and p<0.001 
respectively, robust after FDR) while that of cases with 
NVT increased (p=0.027, also robust after FDR) (Figure 
3A, Table 3). While IPD incidence due to the serotypes 
included in the conjugate vaccines decreased, these 
were still a significant cause of IPD in all age groups, 
accounting for 62.3% (n=43) of the isolates in 2011–
12. When considering individual serotypes (for which 
at least five isolates were detected), the incidence 
of IPD due to serotypes 1 (p<0.001), 19A (p<0.001), 7F 
(p=0.024) and 14 (p=0.015) decreased and increases 
in serotype 10A (p=0.001) were noted. However, only 
the decrease in serotypes 1 and 19A incidence and the 
increase in 10A incidence were supported after adjust-
ment by FDR. 
In contrast to the continual decreases in the number of 
isolates of serotype 1 and 19A during the study period, 
serotype 7F decreased only in 2010–11 after the intro-
duction of PCV10 (Table 4). These resulted in decreases 
in the proportion of isolates of addPCV10 from 37.6% 
in 2008–09 to 20.6% in 2011–12 and of addPCV13 from 
31.6% in 2008–09 to 16.2% in 2011–12.
The overall changes in IPD incidence are the result 
of very different dynamics in the various age groups 
(Figure 3 and Table 3). In the youngest age group (0–11 
months), IPD incidence due to the additional serotypes 
included in the expanded valency conjugate vaccines 
decreased (addPCV10, p=0.006; addPCV13, p<0.001, 
both robust after FDR) while the incidence due to PCV7 
serotypes and NVTs did not change significantly. A 
similar situation occurred in those aged 12–23 months, 
but here only the addPCV13 (p=0.004) was robust after 
FDR.
Table 3
Incidence of invasive pneumococcal infections caused by Streptococcus pneumoniae serotypes included in conjugate vaccine 
formulations by age group, Portugal, July 2008–June 2012a
Age group Serotype group
Incidenceb (95% confidence intervals)
2008–09 2009–10 2010–11 2011–12
0–17 years
PCV7 1.75 (1.26–2.44) 1.41 (0.97–2.04) 0.82 (0.51–1.34) 1.10 (0.72–1.69)
PCV10 4.98 (4.09–6.07) 3.66 ( 2.90–4.61) 2.01 (1.47–2.75) 2.17 (1.60–2.94)
PCV13 7.50 (6.38–8.81) 5.27 (4.34–6.39) 3.10 (2.41–3.99) 2.87 (2.21–3.74)
NVT 0.69 (0.41–1.17) 1.68 (1.20–2.36) 1.41 (0.97–2.05) 1.65 (1.16–2.33)
All serotypes 8.19 (7.06–9.55) 6.95 (5.92–8.22) 4.51 (3.68–5.56) 4.52 (3.66–5.58)
5–17 years
PCV7 0.33 (0.14–0.79) 0.38 (0.17–0.85) 0 (0–0.27) 0 (0–0.27)
PCV10 2.17 (1.53–3.07) 1.65 (1.11–2.46) 0.83 (0.47–1.46) 1.17 (0.72–1.88)
PCV13 2.67 (1.95–3.65) 2.10 (1.48–3.00) 1.51 (0.99–2.30) 1.17 (0.72–1.88)
NVT 0.08 (0.02–0.41) 0.53 (0.26–1.06) 0.38 (0.17–0.86) 0.53 (0.26–1.07)
All serotypes 2.75 (2.02–3.74) 2.63 (1.92–3.61) 1.89 (1.30–2.75) 1.7 (1.14–2.53)
2–4 years
PCV7 1.36 (0.55–3.38) 2.02 (0.94–4.33) 0.41 (0.08–2.00) 2.36 (1.14–4.88)
PCV10 9.5 (6.67–13.55) 8.07 (5.47–11.9) 3.67 (2.05–6.55) 3.14 (1.67–5.92)
PCV13 11.31 (8.17–15.66) 9.58 (6.71–13.69) 4.07 (2.35–7.07) 5.11 (3.10–8.42)
NVT 0 (0–1.21) 1.01 (0.35–2.90) 1.22 (0.46–3.26) 2.36 (1.14–4.88)
All serotypes 11.31 (8.17–15.66) 10.59 (7.54–14.87) 5.30 (3.26–8.60) 7.46 (4.93–11.3)
12–23 months
PCV7 12.15 (7.00–21.08) 7.98 (4.08–15.61) 6.84 (3.25–14.38) 7.03 (3.41–14.52)
PCV10 14.57 (8.80–24.14) 11.40 (6.48–20.04) 6.84 (3.25–14.38) 7.03 (3.41–14.52)
PCV13 27.93 (19.37–40.29) 20.51 (13.44–31.32) 13.67 (8.03–23.27) 9.04 (4.76–17.19)
NVT 3.64 (1.37–9.71) 5.70 (2.59–12.53) 7.98 (4.00–15.92) 7.03 (3.40–14.52)
All serotypes 31.58 (22.37–44.57) 26.21 (18.02–38.13) 21.65 (14.16–33.1) 16.08 (9.9–26.12)
0–11 months
PCV7 12.75 (7.48–21.71) 7.70 (3.83–15.45) 8.01 (4.07–15.78) 7.38 (3.58–15.18)
PCV10 21.24 (14.04–32.16) 10.99 (6.12–19.76) 9.15 (4.85–17.28) 8.85 (4.57–17.15)
PCV13 43.55 (32.57–58.23) 21.99 (14.48–33.38) 12.59 (7.30–21.69) 14.75 (8.81–24.71)
NVT 8.50 (4.44–16.26) 16.49 (10.19 – 26.68) 10.30 (5.65 – 18.77) 10.32 (5.59–19.08)
All serotypes 52.05 (39.9–67.90) 38.48 (28.04 – 52.81) 22.89 (15.25 – 34.34) 25.08 (16.85–37.31)
NVT: non-vaccine serotypes; PCV: pneumococcal conjugate vaccine.
a Epidemiological years: from week 26 of one year to week 25 of the following year.
b Number of cases per 100,000 in specified age group.
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In patients aged 2–4 years, there was no significant 
change in IPD incidence due to addPCV13, but there 
was a substantial decrease in IPD incidence due to 
the addPCV10 serotypes (p<0.001) accompanied by an 
increase in IPD incidence due to NVTs (p=0.007), both 
supported after adjustment by FDR. In the older age 
group (5–17 years), in which no individuals were vac-
cinated with PCV10 or PCV13, the decreases in IPD inci-
dence due to addPCV10 and addPCV13 serotypes were 
not statistically significant: the only significant change 
was the decrease in IPD incidence due to PCV7 sero-
types (p=0.006, robust after FDR).
Antimicrobial susceptibility
Resistance to the tested antimicrobials is summa-
rised in Figure 2 and Table 5. Overall, 110/392 isolates 
(28.1%) were non-susceptible to penicillin (PNSP): 82 
(20.9%) expressed low-level resistance and 28 (7.1%) 
high-level resistance [17]. Considering the current CLSI 
breakpoints for parenteral penicillin [16], 16/39 isolates 
from CSF would have been considered resistant and 
three isolates (0.8%) from 353 non-meningitis cases 
would have been considered non-susceptible, all inter-
mediately resistant. Resistance to erythromycin (ERP) 
was found in 103/392 isolates (26.0%), of which 78 
isolates (75.7%) expressed the MLSB phenotype and 25 
(24.3%) the M phenotype. All isolates were susceptible 
to levofloxacin, vancomycin and linezolid. The simulta-
neous expression of erythromycin resistance and peni-
cillin non-susceptibility (EPNSP) was found in 64/392 
(16.3%) of the isolates. Within the study period, there 
was a modest decrease in ERP (when comparing 36/133 
(27.1%) in 2008–09 with 16/68 (23.5%) in 2011–12) and 
a more noticeable decrease in PNSP (when compar-
ing 45/133 (33.8%) in 2008–09 with 14/68 (20.6%) in 
2011–12).
Figure 2
Streptococcus pneumoniae isolates expressing serotypes present in conjugate vaccines causing invasive pneumococcal 
infections, Portugal, July 2008–June 2012 (n=392)
EPNSP: isolates presenting both erythromycin resistance and penicillin non-susceptibility; ERSP: erythromycin-resistant isolates; NVT: non-
vaccine serotypes; PNSP: penicillin non-susceptible isolates.
The number of isolates expressing each serotype in each of the age groups considered is shown. The serotypes included in each of the 
conjugate vaccines are indicated by the arrows and the percentage of the total number of isolates expressing the serotypes included in 
each of the vaccines is indicated. A total of 27 NVT were detected, representing 90 isolates as follows: 10A, 15A and 23B (n=7 each); 22F 
(n=6); 8, 15B, 15C, 21 and 24F (n=5 each); 25A (n=4); 9N, 11A, 20, 24A, 33A and non-typable (n=3 each); 6C, 16F, 29, 33F and 35F (n=2 
each); 7C, 12B, 18B, 28A, 34 and 45 (n=1 each).
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Figure 3
Incidence of invasive pneumococcal disease due to vaccine serotypes in patients aged under 18 years, Portugal, July 2008–
June 2012a
NVT: non-vaccine serotypes; PCV7: 7-valent pneumococcal conjugate vaccine. 
a Epidemiological years: from week 26 of one year to week 25 of the following year.
b Number of cases per 100,000 in specified age group.
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Together, serotypes 19A and 14 contributed greatly to 
ERP (62/103, 60.2%) and PNSP (64/110, 58.2%) (Figure 
2). Serotypes included in PCV10 represented 33/46 
(71.7%), 21/39 (53.8%) and 17/64 (26.6%) of PNSP, ERP 
and EPNSP, respectively, while serotypes included in 
PCV13 constituted 41/46 (89.1%), 32/39 (82.1%) and 
49/64 (76.6%), respectively.
Discussion
The most important finding of our study is the 
decrease in incidence of IPD in all age groups analysed. 
Moreover, the changes in distribution of the serotypes 
of pneumococci causing IPD in Portugal that accom-
panied the introduction of PCV7 [9,10] have continued 
with the introduction of PCV10 and PCV13. Overall, IPD 
incidence due to the serotypes included in the PCVs 
decreased (Table 3 and Figure 3A): this affected partic-
ularly the additional serotypes included in PCV10 and 
PCV13 and to a lesser extent the serotypes included in 
PCV7. The incidence of IPD means that the actual num-
ber of isolates per serotype in each epidemiological 
year is small (Table 4). This is even more marked when 
stratifying by age group and in the last years of the 
study, due to the decrease in IPD incidence.
The reasons behind the persistence of PCV7 sero-
types as causes of IPD may be multifactorial [12,20]. 
Chief among those could be the slower uptake and 
lower vaccination coverage in Portugal when com-
pared with countries where PCV7 was introduced in the 
national immunisation plan [1,2]. As with serotype 19A 
(see below), the high proportion of resistant isolates 
expressing PCV7 serotypes, particularly to penicillin 
and macrolides, could be an important factor in their 
persistence. Serotype 14, which is known to represent 
more virulent clones [21], remains the most important 
PCV7 serotype in IPD. In contrast to our data, a recent 
study in Portugal found the virtual elimination of PCV7 
serotypes from nasopharyngeal carriage, with the 
exception of serotype 19F, a serotype already associ-
ated with carriage before the introduction of PCVs [22].
The serotype dynamics underpinning the changes in 
IPD incidence were different in the various age groups. 
In the youngest children (under 2 years), including 
those vaccinated with either PCV10 or PCV13, there 
were decreases in IPD caused by the serotypes included 
in the PCVs (Figure 3, B and C). While a reduction in 
Table 4
Serotypes of the isolates responsible for invasive 
pneumococcal disease in patients aged under 18 years, 
Portugal, July 2008–June 2012a (n=392)
Serotype
Number of isolates
2008–09 2009–10 2010–11 2011–12
1 33 20 14 7
3 2 3 1 3
4 1 0 0 1
5 2 0 0 0
6A 5 5 5 3
6B 5 2 2 3
7F 15 15 6 7
9V 0 0 1 0
14 13 12 6 5
18C 0 3 0 1
19A 35 19 13 5
19F 5 2 3 4
23F 5 4 2 4
NVT 12 29 24 25
Total 133 114 77 68
NVT: non-vaccine type.
a Epidemiological years: from week 26 of one year to week 25 of the 
following year.
Table 5
Antimicrobial resistance of Streptococcus pneumoniae 
isolates responsible for invasive pneumococcal disease in 
patients aged under 18 years, Portugal, July 2008–June 
2012a (n=392)
Antibiotic
Number of resistant isolates (%)b
0–11 
months 
(n=121)
12–23 
months 
(n=84)
2–4 years 
(n=78)
[5–17 years 
(n=109)
PENc 43 (35.5) 38 (45.2) 15 (19.2) 14 (12.8)
MIC90 0.75 1.5 0.75 0.064
MIC50 0.023 0.032 0.016 0.016
CTX 4 (3.3) 7 (8.3) 1 (1.3) 2 (1.8)
MIC90 0.75 0.75 0.5 0.125
MIC50 0.023 0.032 0.023 0.023
CRO 6 (5.0) 4 (4.8) 0 (0.0) 2 (1.8)
MIC90 0.75 1 0.5 0.125
MIC50 0.032 0.032 0.032 0.023
ERY 46 (38.0) 29 (34.5) 15 (19.2) 13 (11.9)
CLI 34 (28.1) 23 (27.4) 13 (16.7) 8 (7.3)
CHL 6 (5.0) 4 (4.8) 0 (0.0) 4 (3.7)
SXT 27 (22.3) 21 (25.0) 16 (20.5) 15 (13.8)
TET 29 (24.0) 21 (25.0) 11 (14.1) 13 (11.9)
CHL: chloramphenicol; CLI: clindamycin; CRO: ceftriaxone; CTX: 
cefotaxime; ERY: erythromycin; LEV: levofloxacin; MIC:  minimal 
inhibitory concentration; PEN: penicillin; SXT: trimethoprim-
sulfamethoxazole; TET: tetracycline.
a  Epidemiological years: from week 26  of one year to week 25 of 
the following year.
b  Unless otherwise specified.
c  Number of isolates and percentage of penicillin non-susceptible 
isolates is indicated. 
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incidence due to addPCV10 could be expected in 
2009–10, since the PCV10 vaccine was available from 
the outset of the epidemiological year, the reduction in 
incidence due to addPCV13 occurred in spite of PCV13 
becoming available only in early 2010. IPD incidence 
due to PCV7 serotypes decreased slightly, but not sig-
nificantly: these serotypes remain important causes of 
IPD in spite of more than a decade of PCV7 use.
The 2–4 years age group started including children 
potentially vaccinated with at least one dose of PCV10 
or PCV13 in 2010–11. In this age group, there was a 
strong decrease in the IPD incidence due to addPCV10 
serotypes already in 2009–11 (Figure 3D), whereas 
no significant change was seen in incidence due to 
addPCV13. In the older age group, (5–17 years), the 
decreases in IPD incidence caused by addPCV10 occur-
ring between 2008–09 and 2010–12 and those due to 
addPCV13 serotypes in 2011–12 were not statistically 
significant. Taken together, our data suggest that there 
may be different reasons for the decreases in the inci-
dence due to the various serotypes included in both 
PCV10 and PCV13 and those included only in PCV13.
Limited data available from observational studies 
in different geographical regions have documented 
decreases in IPD incidence due to PCV13 serotypes fol-
lowing PCV13 introduction and of serotypes 1 and 19A 
in particular [6,7]. A field study showed clear effec-
tiveness of PCV13 against serotype 19A IPD [4], while 
another study demonstrated reduced nasopharyngeal 
acquisition of both serotypes 1 and 19A [8].
Decreases in the proportion of isolates expressing 
serotypes 1 and 5, included in both PCV10 and PCV13, 
and of serotype 6A, included only in PCV13, were noted 
in the adult (≥18 years) population in Portugal between 
2009 and 2011 [12]. In contrast, the proportion of iso-
lates expressing serotype 19A, also included only in 
PCV13, did not change significantly as a cause of IPD 
in the adult population in the country [12]. The herd 
effect that is known to occur due to PCV7, and now 
also expected for PCV10 and PCV13, is predicted to be 
delayed relative to the effects on the vaccinated chil-
dren [2,9,23]. It is therefore unlikely that the changes 
seen in adults, and now in older unvaccinated paedi-
atric age groups, can be attributed to PCV use. These 
data emphasise the importance of unexplained tem-
poral trends in the distribution of pneumococcal sero-
types [24] as potential confounders in observational 
studies such as ours. Similar to our observations, a 
vaccine trial in Alaska saw decreases in the incidence 
of PCV13 serotype IPD even before a direct effect of 
vaccination would be expected [20].
Although marked fluctuations in the incidence of sero-
type 1 IPD have been known to occur, no such changes 
have been documented in IPD due to serotype 19A, one 
of the most important serotypes that emerged in the 
post-PCV7 era and a serotype that remains a stable 
cause of IPD in adults in Portugal [10,12,25]. Another 
important difference between isolates expressing 
these two serotypes is their antimicrobial resistance. 
While serotype 1 isolates are mostly susceptible to the 
antimicrobials most frequently used to treat pneumo-
coccal infections, serotype 19A isolates are frequently 
resistant to penicillin and the macrolides [10,24,25], 
a characteristic that has been maintained throughout 
the study period (Figure 2).
Our data argue that factors other than vaccination, such 
as unrelated temporal trends, triggered the decrease 
in the incidence of the two serotypes that had become 
the leading causes of paediatric IPD in the post-PCV7 
years: serotypes 1 and 19A (Table 4) [10]. The reason 
for these changes remains unknown and may be dif-
ferent for these two serotypes. However, even if the 
observed serotype changes were not triggered by vac-
cination, PCV use might have reinforced them. 
Although the decreases in incidence of PCV13 sero-
types were partly offset by an increase in incidence of 
NVT IPD, the overall result was a substantial reduction 
in the incidence of paediatric IPD. An increase in NVT 
IPD incidence was noted in most age groups, although 
only in the 2–4 year-olds was this increase statistically 
significant. The decrease in the incidence of cases 
due to PCV13 serotypes resulted in multiple serotypes 
becoming more prominent causes of IPD, leading to 
increased serotype diversity of IPD cases. Serotype 
10A was the only NVT serotype rising significantly in 
an overall analysis. However, this serotype was not 
among the most frequent NVT serotypes detected in a 
carriage study [22] nor was it found to be particularly 
invasive [21], raising the possibility that this will not be 
a sustained increase.
The decrease in overall PNSP during the study period 
reflected primarily the decrease of serotype 19A. When 
comparing with previous data [10], resistance to peni-
cillin and cefotaxime remained unchanged in all age 
groups and there was a modest decline in ceftriaxone 
resistance. On the other hand, resistance to erythro-
mycin and clindamycin rose in the youngest children 
(aged <2 years) but remained approximately constant 
in the older age groups. Serotype 19A and the PCV7 
serotypes, particularly serotype 14, remained the most 
important serotypes in terms of resistance, suggesting 
a potential influence of PCVs in the dynamics of antimi-
crobial resistance.
Since the criterion for identification of an IPD case is 
the isolation of pneumococci from a normally sterile 
body site or the identification of pneumococcal DNA 
in cerebrospinal fluid (CSF) or pleural fluid, and this 
is almost exclusively done in hospital laboratories, 
we believe that few cases of laboratory-confirmed IPD 
would have been diagnosed outside of our network. The 
active nature of the surveillance and the involvement of 
a large number of hospitals covering the entire coun-
try offer further reassurance that our surveillance sys-
tem identified most cases. We cannot guarantee that 
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the serotype distribution of the cases where isolates 
were unavailable followed the serotype distribution of 
available isolates, but we consider that the approach 
adopted minimises potential bias and describes the 
actual situation. However, the small proportion of 
cases with unknown serotype information ensures that 
our extrapolation does not affect the results. 
In spite of substantial decreases in PCV13 IPD incidence 
in all age groups (Table 3), these serotypes remain 
the most important causes of IPD, being responsible 
for 63.2% of IPD cases in patients under 18 years in 
2011–12 (Table 4). The persistence of these serotypes, 
including the PCV7 serotypes that have been subject 
to vaccine pressure for more than a decade, suggests 
that this could be due to the relatively modest vacci-
nation coverage in Portugal. Coverage peaked around 
2008 at 75% but declined to 63% in 2012 (data not 
shown), a lower coverage than in countries where PCVs 
are in the national immunisation plan and highlighting 
the potential benefits of increasing vaccination cover-
age. Although the study period is probably too close 
to vaccine introduction to expect a herd effect in older 
unvaccinated children, the relatively lower vaccination 
coverage may also compromise the extent of this effect. 
This may reduce the overall benefits of vaccination, 
including the potential protection of infants younger 
than 90 days [26] who are not currently protected by 
direct vaccination. Continued surveillance will monitor 
the extent of PCV13 success by evaluating the capac-
ity of PCV13 serotypes to persist in spite of vaccina-
tion and in documenting the changes in antimicrobial 
resistance that accompany the changing serotypes and 
the emergence of any NVT replacement serotypes.
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